Intelligent, informed, innovative

Experience the difference with College Hill Life Sciences

Your science, our speciality

College Hill Life Sciences brings together a unique mix of expertise in corporate, financial, marketing and product communications with a dedicated design consultancy. We’ve earned a formidable reputation for creative, comprehensive and effective communications counsel over two decades.

Our expertise

Life Sciences, your space, our space

We understand the needs and drivers of the Life Science sector. We’ve been directors, managers, bench scientists, advisors, journalists, editors and accountants - we tailor this industry insight and experience to deliver informed communication and design solutions to showcase your company, product or technology.

Meet our people

Global reach, tailored partnership approach

We are an international business communications consultancy with bases in Europe, USA and Australia and an international client list. We partner with biotech, pharma, medical device and diagnostic companies, VCs, not for profit organisations and businesses that supply technologies, services and laboratory supplies.

Our clients | Visit our offices

Client News

May 24, 2013
BioInvent Recruits Michael Oredsson As New CEO

May 22, 2013
Phagenesis Expands Series B Financing to $17 million

Read more client news



College Hill Clients’ 1st and 5th Largest Capital Raisings in Life Sciences in 2013 to Date

In March College Hill Life Sciences’ ASX-listed client Mesoblast closed AU$170 million (US$176 million) in a private placing with institutional investors. Based on BioWorld’s Insight report issued early March, this is the largest Life Sciences private financing of a public company globally of 2013, just pipping the amounts raised by US-based Ironwood Pharmaceuticals (NASDAQ) and OPKO Health Inc. (NYSE) in January. AIM-listed client, e-Therapeutics, which raised £40 million (US$63m) from an issue of new shares in February, would place it as the fifth largest financing according to figures in the BioWorld report.

View press release